Contact

X-Ray Crystallography (XRC)

The generation of high-resolution structures via x-ray crystallography adds significant value to discovery programs, providing detailed mapping of the interaction site and mode of binding for hit or lead molecules to their target macromolecule. The supply of reliable structure information enables ligand efficient optimisation to provide potent and selective leads for advancement towards development.

XRC – X-Ray Crystallography

Sygnature Discovery’s protein science division, Peak Proteins is a provider of high quality protein reagents and expert x-ray crystallography services. The division utilises its vast expertise to create specialised constructs for the development of Bespoke in vitro Biological Assays and offers crystallographic support for enhancing Structure-based and Fragment-based drug discovery programs.

X-Ray Crystallography (XRC)

Figure A: Crystal structure of the BabA extracellular domain solved by single-wavelength anomalous diffraction (SAD). Image courtesy of Peak Proteins.

Peak Proteins is Sygnature’s partner of choice for the provision of:

  • Wide-ranging knowledge and experience to devise and tailor crystallisation screens for target proteins
  • Expertise in the interpretation of initial hits and optimisation of conditions through iterative rounds of screening
  • Extensive experience in the engineering of proteins to improve crystallisation
  • Thorough knowledge of interpretation of crystal structure data providing insightful protein structure function relationship information
    • Refinement, analysis and modelling using state-of-the-art software
    • Wealth of industrial experience of successfully progressing:
      • de-novo X-ray crystal structure determination of unprecedented proteins
      • High-throughput generation of protein-ligand complexes for structure-based drug design (SBDD)
      • Fragment based lead discovery
    • The depth of experience working with medicinal chemists to exploit structural data to drive chemistry design across multiple proteins and target class

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…